- Home
- ELVA vs ZNTL Comparison
ELVA vs ZNTL Comparison
Compare ELVA & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVA
- ZNTL
- Stock Information
- Founded
- ELVA 1996
- ZNTL 2014
- Country
- ELVA Canada
- ZNTL United States
- Employees
- ELVA N/A
- ZNTL N/A
- Industry
- ELVA
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- ELVA
- ZNTL Health Care
- Exchange
- ELVA Nasdaq
- ZNTL Nasdaq
- Market Cap
- ELVA 125.5M
- ZNTL 105.8M
- IPO Year
- ELVA N/A
- ZNTL 2020
- Fundamental
- Price
- ELVA $3.69
- ZNTL $1.41
- Analyst Decision
- ELVA Strong Buy
- ZNTL Buy
- Analyst Count
- ELVA 5
- ZNTL 7
- Target Price
- ELVA $6.10
- ZNTL $8.60
- AVG Volume (30 Days)
- ELVA 85.0K
- ZNTL 1.4M
- Earning Date
- ELVA 08-12-2025
- ZNTL 08-08-2025
- Dividend Yield
- ELVA N/A
- ZNTL N/A
- EPS Growth
- ELVA N/A
- ZNTL N/A
- EPS
- ELVA N/A
- ZNTL N/A
- Revenue
- ELVA $48,016,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- ELVA $55.29
- ZNTL N/A
- Revenue Next Year
- ELVA $63.69
- ZNTL N/A
- P/E Ratio
- ELVA N/A
- ZNTL N/A
- Revenue Growth
- ELVA N/A
- ZNTL N/A
- 52 Week Low
- ELVA $1.67
- ZNTL $1.01
- 52 Week High
- ELVA $4.07
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- ELVA 61.07
- ZNTL 55.69
- Support Level
- ELVA $3.71
- ZNTL $1.29
- Resistance Level
- ELVA $4.07
- ZNTL $1.43
- Average True Range (ATR)
- ELVA 0.20
- ZNTL 0.09
- MACD
- ELVA 0.03
- ZNTL 0.02
- Stochastic Oscillator
- ELVA 68.93
- ZNTL 80.00
About ELVA Electrovaya Inc.
Electrovaya Inc designs develop and manufacture proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation and other specialized applications. It is a technology-focused company with extensive IP. The company generates revenue from the sale of batteries and battery systems. Business operations are segmented based on large format batteries and others. This technology offers enhanced safety and battery longevity. Geographically it earns key revenue from the United States.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.